Bluejay Diagnostics Reports Progress on Symphony Platform and 2026 Strategic Outlook

Bluejay Diagnostics provided a corporate update highlighting recent progress and its planned strategic trajectory through 2026. The company is advancing its Symphony platform, including the SYMON II clinical study for the rapid measurement of Interleukin-6 (IL-6) to support sepsis risk assessment and critical-care decision making. Bluejay has achieved meaningful progress in manufacturing readiness, supply-chain initiatives, and external manufacturing coordination. The company expects to report $5.2 million in cash and cash equivalents and $6.0 million in stockholders' equity as of December 31, 2025. Through 2026, Bluejay's primary strategic focus areas include completing the SYMON II study, manufacturing scale-up, supply-chain robustness, and advancing the Symphony platform capabilities.